Active clinical trials with tagraxofusp (SL401)
| Active trial titles . | Area of study . | Clinicaltrials.gov identifier . |
|---|---|---|
| SL-401 in combination with pomalidomide and dexamethasone in R/R MM | MM | NCT02661022 |
| SL-401 in combination with AZA or AZA/VEN in AML or high-risk MDS | MDS, AML | NCT03113643 |
| Tagraxofusp (SL-401) in patients with CMML or MF | MF, CMML | NCT02268253 |
| SL-401, venetoclax, and HCVAD chemotherapy for the treatment of BPDCN | BPDCN | NCT04216524 |
| Tagraxofusp in treating patients with BPDCN after SCT | BPDCN | NCT04317781 |
| Active trial titles . | Area of study . | Clinicaltrials.gov identifier . |
|---|---|---|
| SL-401 in combination with pomalidomide and dexamethasone in R/R MM | MM | NCT02661022 |
| SL-401 in combination with AZA or AZA/VEN in AML or high-risk MDS | MDS, AML | NCT03113643 |
| Tagraxofusp (SL-401) in patients with CMML or MF | MF, CMML | NCT02268253 |
| SL-401, venetoclax, and HCVAD chemotherapy for the treatment of BPDCN | BPDCN | NCT04216524 |
| Tagraxofusp in treating patients with BPDCN after SCT | BPDCN | NCT04317781 |
Source: Clinicaltrials.gov (accessed May 2020).
AZA, azacitidine; MF, myelofibrosis; VEN, venetoclax.